• AAPL 165.065
  • TSLA 149.8999
  • AMZN 176.155
  • MSFT 401.37
  • INTC 34.6213
  • EURUSD 1.0669
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NYSE /
  3. RFL.NYSE

Rafael Holdings Inc Class B (RFL NYSE) stock market data APIs

$1.77 0.06(3.5%) as of April 18, 2024

Rafael Holdings Inc Class B Financial Data Overview

1.71
1.77
-
1.7737
1.6954
1.44-2.52
42 039 K
17.1
23 797 K
275 K
0.2558
1.268
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RFL',
Type: 'Common Stock',
Name: 'Rafael Holdings Inc Class B',
Exchange: 'NYSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00J3YYS92',
ISIN: NULL,
CUSIP: NULL,
CIK: '1713863',
EmployerIdNumber: '82-2296593',
FiscalYearEnd: 'July',
IPODate: '2018-03-26',
InternationalDomestic: 'Domestic',
Sector: 'Real Estate',
Industry: 'Real Estate Services',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Rafael Holdings Inc Class B Fundamental Data is available in our Financial Data APIs

  • Net Revenue 275 K
  • EBITDA -11 478 913
  • Earnings Per Share 0.1
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Rafael Holdings Inc Class B Earnings via APIs

  • Latest Release 2024-03-13
  • EPS/Forecast NaN

Get Rafael Holdings Inc Class B End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Rafael Holdings Inc Class B latest news via APIs

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Rafael Holdings, Inc. Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments NEWARK, N.J., Dec. 14, 202...

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport,...
Do you have any questions?
support@eodhistoricaldata.com